JUNS

Jupiter

--(--)

Market Open: --

--(--)

Post-Market: --

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About JUNS

Jupiter Neurosciences, Inc.

A clinical stage drug platform company specializing in the treatment of neuroinflammation

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

12/03/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.jupiterneurosciences.com

Security Type

Common stock

Office address

1001 North US HWY 1, Suite 504, Jupiter, Florida 33477

Business

Introduction

Jupiter Neurosciences, Inc., was incorporated in Delaware in January 2016. The company is a clinical stage research and development pharmaceutical company. The company has developed a unique resveratrol platform product for the treatment of neuroinflammation. The product, called JOTROL, has a number of potential indications for rare diseases, primarily for mucopolysaccharidosis type 1, Friedreich's ataxia and MELAS, as well as ALS in early development. The company will be highly focused on the expected positive impact of JOTROL on neuroinflammation in all indications they are seeking. Based on the available scientific literature, they believe that JOTROL is the first and only resveratrol product in the world that provides a therapeutic effective dose of resveratrol in the blood without causing gastrointestinal (GI) side effects.